Revenues for the quarter ended Sept. 30 increased to $20.2 million from $16.5 million during the same period last year. Caliper said that during the last three months, Merck, Johnson & Johnson, and Taisho Pharmaceutical of
Caliper spent $5.3 million on R&D during the quarter, down from $8.8 million a year ago.
The company's net loss was cut in half, to $5.1 million, or $.17 per share, compared to $10.1 million, or $.37 per share, during the third quarter of 2003.
As of Sept. 30, Caliper had $6.1 million in cash and cash equivalents and $43.1 million in short-term marketable securities.